219 related articles for article (PubMed ID: 1695795)
1. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
Balmer CM
DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
[TBL] [Abstract][Full Text] [Related]
2. Current status of interferons in the treatment of cancer.
Hansen RM; Borden EC
Oncology (Williston Park); 1992 Nov; 6(11):19-24; discussion 26, 29. PubMed ID: 1280153
[TBL] [Abstract][Full Text] [Related]
3. Biologic response modifiers: the interferon alfa experience.
Koeller JM
Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S11-5. PubMed ID: 2481396
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy: the interferon-alpha experience.
Kirkwood J
Semin Oncol; 2002 Jun; 29(3 Suppl 7):18-26. PubMed ID: 12068384
[TBL] [Abstract][Full Text] [Related]
5. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
6. Biotherapy with interferon--1988.
Figlin RA
Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
[TBL] [Abstract][Full Text] [Related]
7. The clinical application of the interferons: a review. NSW Therapeutic Assessment Group.
Stuart-Harris RC; Lauchlan R; Day R
Med J Aust; 1992 Jun; 156(12):869-72. PubMed ID: 1376397
[TBL] [Abstract][Full Text] [Related]
8. The interferons. Mechanisms of action and clinical applications.
Baron S; Tyring SK; Fleischmann WR; Coppenhaver DH; Niesel DW; Klimpel GR; Stanton GJ; Hughes TK
JAMA; 1991 Sep; 266(10):1375-83. PubMed ID: 1715409
[TBL] [Abstract][Full Text] [Related]
9. [Interferon in the treatment of solid tumors].
Lukac J; Seso D; Daković N; Ferencić Z; Cajkovac V; Belicza M; Soos E; Ikić D; Kusić Z
Lijec Vjesn; 1994; 116(11-12):303-7. PubMed ID: 7536287
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of cytokine treatment in malignant skin tumors.
Garbe C
Recent Results Cancer Res; 1995; 139():349-69. PubMed ID: 7597303
[TBL] [Abstract][Full Text] [Related]
11. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
12. The role of interferons in the treatment of malignant neoplasms.
Murren JR; Buzaid AC
Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
[TBL] [Abstract][Full Text] [Related]
13. Interferons in oncology.
Woll PJ; Pettengell R
Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
[TBL] [Abstract][Full Text] [Related]
14. [Current status of interferon therapy].
Dittrich C
Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
[TBL] [Abstract][Full Text] [Related]
15. Interferons in the treatment of multiple myeloma.
Cooper MR; Welander CE
Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
[TBL] [Abstract][Full Text] [Related]
16. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia.
Fuggetta MP; D'Onofrio C; Bonmassar E
Ann Ist Super Sanita; 1990; 26(3-4):385-95. PubMed ID: 1708953
[TBL] [Abstract][Full Text] [Related]
17. Interferons and interleukins in metastatic renal cell carcinoma.
Choudhury M; Efros M; Mittelman A
Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
[TBL] [Abstract][Full Text] [Related]
18. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
19. The role of interferons in the treatment of solid tumors.
Wadler S
Cancer; 1992 Aug; 70(4 Suppl):949-58. PubMed ID: 1379117
[TBL] [Abstract][Full Text] [Related]
20. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
Oettgen HF
Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
